Colorectal cancer is linked to the excessive consumption of red meat, ultra-processed foods, high rates of obesity and a sedentary lifestyle, among other factors that would underlie the rise of this digestive-type disease that has even surpassed the rates of lung cancer, which continues being the first cause of death from cancer in our country. Currently, colorectal cancer is the third leading cause of cancer death in the country. A situation that could change if these new cases were diagnosed and treated in time. This is highlighted by Dr. Jaime González, medical supervisor at the Bradford Hill Clinical Research Center, “in these types of diseases, the development of new treatments and therapies that help patients improve their quality of life is crucial.”

The ESMO TAT Congress, held in Paris, was the setting for presenting the latest scientific advances in oncology, primarily focused on early phase (phase 1) clinical studies. In this context, Chilean oncologist Carlos Rojas, director of the Bradford Hill Clinical Research Center, presented a multicenter phase 1 study that promises to open new perspectives in cancer treatment. Specifically, through a therapy directed against the KRAS G12C mutation, a genetic alteration present in up to 1 in 4 cancer patients, particularly in lung and colon tumors.

Worrying cancer mortality figures in the Antofagasta Region in recent years have prompted a group of oncologists to open the first clinical research center in the north of the country. Bradford Hill North will engage in multinational clinical studies on the types of cancer with the highest incidence in the region.